Your session is about to expire
Aimovig vs Botox
Introduction
For patients with chronic migraines, certain medications can help in reducing the frequency and severity of these debilitating headaches. Aimovig and Botox are two such drugs that have been approved for migraine prevention. Both work by blocking signals in the nervous system associated with pain.
Aimovig, also known as erenumab, is a monoclonal antibody that specifically targets the calcitonin gene-related peptide (CGRP) receptor thought to play a critical role in migraine attacks. It's self-injected once a month and directly inhibits one part of CGRP function.
On the other hand, Botox or botulinum toxin type A works by blocking nerve signals leading to muscle contraction, thus reducing muscle stiffness and spasms often associated with chronic migraines. Administered through multiple injections around your head and neck every 12 weeks, it helps prevent migraines before they start.
Aimovig vs Botox Side By Side
| Attribute | Aimovig | Botox |
|---|---|---|
| Brand Name | Aimovig | Botox |
| Contraindications | Allergy to any of Aimovig's ingredients, severe allergies to latex or rubber-like substances due to the needle cap, severe liver disease without consulting a doctor | Allergy to any of Botox's ingredients, muscle disorders, difficulty swallowing/breathing issues |
| Cost | Around $600 for one injection pen (70 mg) | Ranges from $300 - $1000 per session |
| Generic Name | Erenumab | Botulinum toxin type A |
| Most Serious Side Effect | Signs of an allergic reaction, potential heart issues, high blood pressure symptoms, unusual bleeding, constipation that does not go away | Difficulty breathing which can be life-threatening due to spreading toxin effect, muscle weakness all over the body, vision problems, loss of bladder control |
| Severe Drug Interactions | Not specifically mentioned, but it's important to tell your physician which medications you are taking to prevent dangerous interactions | Not specifically mentioned, but it's crucial to share detailed medical history with healthcare provider prior to beginning treatment |
| Typical Dose | 70-140 mg/month | 155 Units to 195 Units every 12 weeks |
What is Aimovig?
Erenumab (the generic name for Aimovig) is a ground-breaking medication that was specifically created to prevent migraines, marking a significant development in comparison to previously available treatments. Erenumab was first approved by the FDA in 2018 and operates as a CGRP inhibitor, effectively blocking the CGRP receptor which plays a crucial role in migraine attacks. It's prescribed primarily for the prevention of episodic and chronic migraines. On another note, Botox has been traditionally used for cosmetic purposes but has also found its place as an effective treatment method for chronic migraines since its approval by the FDA in 2010. While both medications can be used to manage migraine conditions, their mechanisms differ significantly; Aimovig directly targets molecules involved with nerve inflammation during migraines while Botox interferes with signal transmission among nerves thereby inhibiting muscle contractions related to pain pathways.
What conditions is Aimovig approved to treat?
Aimovig is approved for the treatment of various types of migraines:
- Episodic Migraine, which refers to patients who have a migraine on fewer than 15 days per month
- Chronic Migraine, defined as experiencing a headache on 15 or more days per month for at least three months
On the other hand, Botox is also approved by FDA not only for cosmetic purposes but also in preventing chronic migraines. It's considered when headaches occur 15 or more times a month over a period of three months.
How does Aimovig help with these illnesses?
Aimovig helps to manage migraines by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is a protein located on the surface of cells and plays a critical role in triggering migraines. The CGRP can cause inflammation and dilation of blood vessels in the brain, both of which are associated with migraine pain. By inhibiting this action at its source, Aimovig prevents these symptoms from occurring. This differs from other treatments that work by treating symptoms after they have already begun.
Botox or Botulinum toxin type A works differently. It's primarily known for its use in cosmetic treatments but it also has therapeutic applications such as treating chronic migraines. Botox is injected into specific points around the head and neck every three months to help prevent future headache attacks before they start by reducing muscle contractions and blocking pain signals being sent to the brain.
Both medications aim at preventing migraine attacks rather than dealing with them once they occur, providing patients with more control over their condition.
What is Botox?
Botox, the brand name for Botulinum toxin type A, is a neuromuscular blocking agent initially approved by the FDA in 1989. It works by inhibiting acetylcholine release at the neuromuscular junction, leading to muscle paralysis. This unique action has found Botox applications not just in cosmetics for reducing wrinkles but also medically in treating conditions like dystonia and migraine. In terms of migraines specifically, unlike Aimovig which functions as a CGRP inhibitor preventing vasodilation associated with migraines, Botox interrupts pain pathways that contribute to chronic migraines directly within nerves themselves. Its side-effect profile is different from that of CGRP inhibitors like Aimovig; most commonly reported ones include injection site discomfort and eyelid drooping if used cosmetically around eyes. The effects on interrupting pain signal transmission can be beneficial for managing chronic migraines especially when first-line treatments have failed or are not tolerated well.
What conditions is Botox approved to treat?
Botox has been approved by the FDA for treatment of several conditions, including:
- Chronic migraines: It is designed to reduce headache frequency in adults suffering from chronic migraines.
- Upper limb spasticity: Botox can be used in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors, and finger flexors.
- Cervical dystonia: For adults who experience severe neck pain and abnormal head position associated with this condition.
How does Botox help with these illnesses?
Botulinum toxin, commonly known as Botox, plays a role in many processes in the body. It works by blocking signals from the nerves to the muscles, thus preventing muscle contractions and reducing muscular tension. This makes it useful for treating conditions like dystonia and spasticity. In relation to migraines, Botox is thought to work by obstructing pain pathways associated with headache. Its action on nerve endings may play a significant role in its effectiveness against chronic migraines. Since it doesn't directly affect CGRP levels (a protein involved in migraine attacks), it can be prescribed when patients do not respond well to typical CGRP inhibitors such as Aimovig or may be combined with these medications for better results.
How effective are both Aimovig and Botox?
Both Erenumab (Aimovig) and OnabotulinumtoxinA (Botox) are approved by the FDA for preventing chronic migraines, with Aimovig having been approved most recently in 2018. They act on different mechanisms to prevent migraine attacks, so they may be prescribed under varying circumstances. The effectiveness of Aimovig and Botox was directly compared in a clinical trial in 2020; both drugs showed comparable efficacy in reducing monthly migraine days.
A review of three large phase III trials published between 2017-2018 demonstrated that Aimovig significantly reduces monthly migraine days and is well-tolerated among patients suffering from episodic or chronic migraines. It has quickly gained popularity due its unique mechanism as a CGRP receptor antagonist - marking an innovative approach to treating migraines. A once-monthly subcutaneous injection at doses of either 70 mg or 140 mg appears optimal for maintaining therapeutic effect while minimizing side effects.
On the other hand, according to a Cochrane review from 2014, Botox has proven effective against chronic migraines but not those classified as episodic (less than fifteen headache days per month). This treatment involves multiple injections around the head and neck every twelve weeks which can be inconvenient for some patients. Despite this inconvenience factor, it remains a popular option thanks to its long-established history dating back to initial approval over thirty years ago for cosmetic indications initially then later expanded including for use against chronic headaches.
Related trials for aimovig and botox
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Aimovig typically prescribed?
Subcutaneous dosages of Aimovig range from 70-140 mg/month, but studies have shown that a dose of 70 mg/month is usually sufficient for preventing migraines in most people. Some patients may benefit from an increased dosage to 140mg/month if there isn't any response after a few months. The maximum dosage that should not be exceeded in any case is 140 mg per month. On the other hand, Botox treatment typically involves injections every three months and dosing can vary widely depending on the individual's needs and response to treatment, with typical total doses ranging from 155-195 units per session across various muscles involved in migraine. Always follow your healthcare provider's directions regarding these treatments.
At what dose is Botox typically prescribed?
Botox treatment for chronic migraines generally starts with a dosage of 155 Units, divided into about 31 injections around the head and neck area every 12 weeks. The dose can then be increased to a maximum of 195 Units, dependent on the patient's response to therapy and their tolerance level. It may need more than one treatment cycle to see improvement in symptoms. This should always be administered by a medical professional trained in Botox administration as it is crucial that these injections are precisely placed in specific muscles associated with headache onset for optimal results.
What are the most common side effects for Aimovig?
Common side effects that might occur with Aimovig usage include:
- Pain, redness, or swelling at the injection site
- Constipation
- Cramping
- Muscle spasms
In contrast, common Botox side effects can include:
- Temporary muscle weakness near where the medicine is injected
- Trouble swallowing for several months after treatment
- Muscular stiffness in neck and back
- Headache and flu-like symptoms such as fever and chills
Remember to always consult your doctor if you experience any of these symptoms persistently.
Are there any potential serious side effects for Aimovig?
While both Aimovig and Botox are FDA-approved for the prevention of migraines, they do have potential side effects. For Aimovig, watch out for:
- Signs of an allergic reaction: rash; hives; itching; redness, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; difficulty breathing, swallowing, or talking.
- Potential heart issues: irregular heartbeat
- High blood pressure symptoms: severe headache, blurred vision
- Unusual bleeding
- Constipation that does not go away
For Botox injections used to treat chronic migraines:
- Difficulty breathing which can be a life-threatening condition due to spreading toxin effect. Symptoms may occur hours to weeks after receiving botox.
- Muscle weakness all over the body
- Vision problems
- Loss of bladder control If you experience any of these symptoms after either treatment please seek immediate medical attention as some could potentially be life threatening.
What are the most common side effects for Botox?
The following are some possible side effects of Botox:
- Mild pain, swelling or bruising at the injection site
- Headache or flu-like symptoms
- Droopy eyelid or cockeyed eyebrows
- Crooked smile or drooling
- Eye dryness or excessive tearing
- Difficulty swallowing, speaking, or breathing (if given in neck)
Remember that these effects are temporary and your doctor will monitor you for any serious complications. It's crucial to go to a qualified health professional when considering treatments like Botox.
Are there any potential serious side effects for Botox?
Botox, although widely used and generally safe, can sometimes lead to severe side effects. These may include:
- Signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue or throat
- Muscle weakness all over the body
- Vision problems or blurred vision (Some people report "tunnel vision")
- Drooping eyelids
- Hoarse voice or trouble speaking
- Trouble swallowing or breathing (in extreme cases)
- Loss of bladder control
If you experience any of these symptoms after receiving Botox treatment, it's essential to seek immediate medical attention.
Contraindications for Aimovig and Botox?
Both Aimovig and Botox, along with most other migraine prevention medications, may not be suitable for everyone. If you notice your migraines worsening or new side effects developing after starting these treatments, inform your doctor immediately.
Neither Aimovig nor Botox should be taken if you are allergic to any of their ingredients or have certain health conditions. Always tell your physician which medications you are taking; some drugs require a period of time to clear from the system before introducing either treatment to prevent dangerous interactions.
Aimovig is contraindicated in patients with serious allergies to latex or rubber-like substances as the needle cap contains this material. It should also not be used by people who have severe liver disease without consulting a doctor first.
Botox has its own list of precautions including muscle disorders and difficulty swallowing/breathing issues among others. It's important that you share detailed medical history information with your healthcare provider prior to beginning treatment.
How much do Aimovig and Botox cost?
For the brand name versions of these drugs:
- The price of one injection pen of Aimovig (70 mg) averages around $600, which works out to approximately $20/day when considering a typical monthly dosage.
- The price for Botox treatment varies greatly depending on your specific medical condition and the required dose. However, it typically ranges from $300 - $1000 per session, lasting about three months on average. Thus, daily cost can range from about $3 to $11.
Thus, if you require frequent or high-dose Botox treatments (i.e., more than 200 units every three months), then brand-name Aimovig could potentially be less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
Currently there are no generic versions available for either Aimovig or Botox due to patent protections, so costs remain relatively high compared with many other medications.
Popularity of Aimovig and Botox
Erenumab, commonly known by the brand name Aimovig, is a relatively new drug used for migraine prevention. It was approved by the FDA in 2018 and prescribed to about 100,000 people in its first year on the market. As of current trends, this number has been steadily increasing as it becomes more widely recognized as an effective preventive treatment for migraines.
On the other hand, Botulinum toxin A (Botox) has long been utilized not only for cosmetic purposes but also medical uses including chronic migraine prevention. Botox received FDA approval for this indication back in 2010 and its use has remained steady since then; approximately half a million people receive Botox injections every year specifically for migraine reduction. While both drugs have proven efficacy against migraines, they differ greatly in administration method- Aimovig is self-administered monthly via injection into the skin whereas Botox requires doctor-administered injections into specific points around head and neck every three months.
Conclusion
Both Aimovig (erenumab) and Botox (botulinum toxin type A) are proven treatments for chronic migraines, with their effectiveness supported by numerous clinical studies and meta-analyses indicating that they outperform placebo treatments. Both drugs may be used in combination under certain circumstances, but this requires careful consideration by a physician due to potential drug interactions. Their mechanisms of action differ: Aimovig primarily blocks the CGRP receptor—a key player in migraine pathogenesis—while Botox inhibits the release of various neurotransmitters involved in pain transmission.
Aimovig is administered monthly via injection which can be done at home after initial training, while Botox treatment typically involves injections around the head and neck every 12 weeks administered by a healthcare professional.
Both medications come at high costs; however, patient assistance programs exist for both to help mitigate some of these expenses.
In terms of side effects, both drugs have generally good tolerability profiles. Common side effects with Aimovig include constipation and muscle spasms or stiffness whereas those associated with Botox might include neck pain, headache, or eyelid drooping. It's crucial for patients using either treatment option to monitor their symptoms closely and seek medical help immediately if they notice new or worsening symptoms.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Siddiqui, M., Shah, P. V., Balani, P., Lopez, A. R., Nobleza, C. M. N., & Khan, S. (2021, January 30). Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines. Cureus. Springer Science and Business Media LLC.http://doi.org/10.7759/cureus.13002
- Clark, G. T. (2003, November). The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Physical Medicine and Rehabilitation Clinics of North America. Elsevier BV.http://doi.org/10.1016/s1047-9651(03)00044-5
- Markham, A. (2018, July). Erenumab: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-018-0944-0
- Freitag, F. G. (2007, May). Botulinum toxin type A in chronic migraine. Expert Review of Neurotherapeutics. Informa UK Limited.http://doi.org/10.1586/14737175.7.5.463
- Becker, W. J., Spacey, S., Leroux, E., Giammarco, R., Gladstone, J., Christie, S., … Bastien, N. (2022, April). A real‐world, observational study of erenumab for migraine prevention in Canadian patients. Headache: The Journal of Head and Face Pain. Wiley.http://doi.org/10.1111/head.14291
- Cohen, F., Armand, C., Lipton, R. B., & Vollbracht, S. (2021, March 8). Efficacy and Tolerability of Calcitonin Gene–Related Peptide–Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. Pain Medicine. Oxford University Press (OUP).http://doi.org/10.1093/pm/pnab093
- Silberstein, S., Mathew, N., Saper, J., Jenkins, S., & for the BOTOX Migraine Clinical Research Group. (2000, June 24). Botulinum Toxin Type A as a Migraine Preventive Treatment. Headache: The Journal of Head and Face Pain. Wiley.http://doi.org/10.1046/j.1526-4610.2000.00066.x